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Abstract
Persistent inflammation promotes development and progression of heart failure (HF). TWEAK
(TNF-Related WEAK Inducer Of Apoptosis), a NF-κB- and/or AP-1-responsive proinflammatory
cytokine that signals via TWEAK receptor (TWEAKR), is expressed at high levels in human and
preclinical models of HF. Since the adapter molecule TRAF3IP2 (TRAF3 Interacting Protein 2) is
an upstream regulator of various proinflammatory pathways, including those activated by NF-κB
and AP-1, we hypothesized that targeting TRAF3IP2 inhibits TWEAK induced proinflammatory
and pro-fibrotic responses in vitro and in vivo. Consistent with the hypothesis, forced expression
of TRAF3IP2 upregulated TWEAK and its receptor expression in cultured adult mouse cardiac
fibroblasts (CF). Further, exogenous TWEAK upregulated TRAF3IP2 expression in a time- and
dose-dependent manner, suggesting a positive-feedback regulation of TRAF3IP2 and TWEAK.
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TWEAK also promoted TRAF3IP2 nuclear translocation. Confirming its critical role in TWEAK
signaling, silencing TRAF3IP2 inhibited TWEAK autoregulation, TWEAKR upregulation, p38
MAPK, NF-κB and AP-1 activation, inflammatory cytokine expression, MMP and TIMP1
activation, collagen expression and secretion, and importantly, proliferation and migration.
Recapitulating these in vitro results, continuous infusion of TWEAK for 7 days increased systolic
blood pressure (SBP), upregulated TRAF3IP2 expression, activated p38 MAPK, NF-κB and AP-1,
induced the expression of multiple proinflammatory and pro-fibrotic mediators, and interstitial
fibrosis in hearts of wild type mice. These proinflammatory and pro-fibrotic changes occurred in
conjunction with myocardial hypertrophy and contractile dysfunction. Importantly, genetic
ablation of TRAF3IP2 inhibited these TWEAK-induced adverse cardiac changes independent of
increases in SBP, indicating that TRAF3IP2 plays a causal role, and thus a therapeutic target, in
chronic inflammatory and fibro-proliferative diseases.

Keywords
Fn14; CIKS; Act1; adverse cardiac remodeling; migration

1.

Introduction
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TWEAK (TNF-Related WEAK Inducer Of Apoptosis), a secreted ligand in the TNF
superfamily of ligands (TNF Superfamily member12 or TNFSF12), is a multifunctional
protein that exerts proinflammatory, pro-mitogenic, pro-migratory and pro-apoptotic effects,
depending on the cellular context and the disease process investigated [1–3]. It signals
mainly via TWEAK receptor (TWEAKR; also known as Fn14, Fibroblast Growth FactorInducible Immediate-Early Response Protein 14) [4]. Both TWEAK and TWEAKR are
expressed at low basal levels in various organs, including the heart.
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In the heart, cardiac fibroblasts (CF) express both TWEAK and TWEAKR [1–3,5,6].
Though genetic ablation of TWEAK or its receptor failed to result in developmental defects,
metabolic alterations, or death [7,8], their sustained expression has been shown to amplify
inflammatory responses in the heart, resulting in adverse myocardial remodeling and HF
development. For example, subjects with ST-elevation myocardial infarction, a predisposing
factor for HF development, showed increased circulating levels of TWEAK, with as high a
level as 7500 pg/ml in some individuals compared to ~524 pg/ml in normal controls [9],
possibly contributing to adverse myocardial remodeling in those subjects. In fact, transgenemediated sustained elevation in systemic soluble TWEAK (a 1000-fold increase compared
to non-transgenic littermate controls) or adenoviral-mediated overexpression of full-length
TWEAK has been shown to result in dilated cardiomyopathy, fibrosis, contractile
dysfunction, HF development and early mortality [10]. In those transgenic animal models,
TWEAK expression was under the regulation of liver-specific apolipoprotein E enhancer/
human α-antitrypsin promoter, indicating that sustained increases in systemic TWEAK
levels are detrimental to the heart, irrespective of origin [10]. Surprisingly, though elevated
soluble or membranous TWEAK promoted dilated cardiomyopathy, no cardiomyocyte death
was detected in those models. Importantly, genetic ablation of TWEAKR blocked those
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TWEAK-induced adverse cardiac changes [10], suggesting that targeting TWEAK or its
receptor has the potential to inhibit persistent inflammation and HF development.
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The intracellular domain of TWEAKR contains an amino acid motif (-PIEET-) that binds
various members of the TRAF (TNF receptor-associated factors) family of signaling
adapters, resulting in the activation of multiple downstream signaling pathways [11,12]. For
example, association between TWEAKR and TRAF2 promotes recruitment of cellular
inhibitors of apoptosis and TNFR death domain proteins, resulting in cell survival or death
[13,14]. TWEAK induces TRAF1 expression in an NF-κB-dependent manner [15], and the
interaction between TRAF1 and TRAF2 has been shown to facilitate a crosstalk between
TWEAKR and the receptors for TNF, resulting in amplification of inflammatory signaling.
In a myoblast cell line, the interaction between TWEAKR and TRAF6 has been shown to
inhibit anabolic pathways, but results in the activation of the ubiquitin-proteasome and the
NF-κB systems, culminating in atrophy [16]. These reports indicate that the association
between TWEAKR and various TRAFs results in the activation of multiple proinflammatory
pathways, majority of which lead to NF-κB activation. In addition, interactions between
TWEAKR and TRAFs have also been shown to activate JNK, AP-1 and p38 MAPK [17,18],
whose sustained activation is well known to affect adversely both cardiac structure and
function through sustained inflammation [19,20].
In addition to activating NF-κB and AP-1, TWEAK and TWEAKR are also NF-κB and/or
AP-1-responsive genes [21,22]. Thus, upon induction, TWEAK/TWEAKR signaling
perpetuates inflammation by the sustained induction of their own and that of various other
inflammatory mediators, through a NF-κB- and/or AP-1-dependent mechanism. Of note,
sustained activation of NF-κB and AP-1 has been shown to contribute causally to
myocardial injury, hypertrophy, fibrosis, contractile dysfunction and HF development [21–
23]. We and others have previously reported that the cytoplasmic adapter molecule TRAF3
Interacting Protein 2 (TRAF3IP2, also known as CIKS [Connection To IKK And SAPK/
JNK] or Act1 [NF-Kappa-B Activator 1]) is an upstream regulator of both NF-κB and AP-1,
and plays a causal role in various autoimmune and inflammatory diseases [24–26].
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Structurally, TRAF3IP2 is a 555 amino acid adapter molecule that contains two TRAFinteracting motifs, a helix-loop-helix (HLH) domain to activate IKK, a U-box that plays a
role in ubiquitination of TRAF6 at Lys63 resulting in its activation, and a STIR (similar
expression to fibroblast growth factor genes and interleukin-17 receptors [SEFIR] + TollIL-1 receptor [TIR]) domain that interacts with other SEFIR-domain containing proteins
(e.g., IL-17 receptors) [24–26]. Though TRAF3IP2 contains two TRAF-interacting motifs (EESE-), these sites appear to be mutually redundant since signaling was impaired only when
both TRAF-interacting motifs are mutated. Lys63-mediated polyubiquitination of TRAF6
activates NF-κB via mechanisms similar to those established for IL-18, IL-1, Toll, and
CD40 receptors; i.e., via recruitment of TAK1 (TGF-beta activated kinase 1) and the
ubiquitinbinding proteins TAB1/2 (TGF-β Activated Kinase 1 and 2), resulting in IKK (IκB
kinase) activation [27,28]. We recently demonstrated that TRAF3IP2 physically associates
with IKKγ/NEMO and JNK, and silencing TRAF3IP2 inhibits IKKγ/JNK association and
JNK activation, indicating that TRAF3IP2 may act as a scaffold in IKKγ and JNK physical
association, and AP-1 activation [26].
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Similar to the pathological role played by the enhanced expression of TWEAK and its
receptor, cardiomyocyte-specific transgenic overexpression of TRAF3IP2 results in
sustained activation of the IKK/NF-κB and JNK/AP-1-dependent inflammatory signaling
and the spontaneous development myocardial hypertrophy, fibrosis and contractile
dysfunction [29]. Since TWEAK/TWEAKR signaling activates NF-κB and AP-1 via TRAFdependent mechanisms, and as TRAF3IP2 is an upstream regulator of both transcription
factors, we hypothesized that targeting TRAF3IP2 will not only inhibit TWEAK/TWEAKRinduced NF-κB and AP-1 activation, but also TWEAK autoregulation and TWEAKR
upregulation, resulting in reduced proinflammatory and profibrotic responses both in vitro
and in vivo.

2.
2.1.

Materials and methods
Materials
The materials used in the present study are described in Supplementary methods.

2.2.

In vitro studies
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2.2.1. Animals and cardiac fibroblast (CF) isolation and treatment—This
investigation conforms to the Guide for the Care and Use of Laboratory Animals, published
by the National Institutes of Health (DRR/National Institutes of Health, 1996). All protocols
were approved by the Institutional Animal Care and Use Committees at the University of
Texas Health Science Center, San Antonio, TX and the Tulane University, New Orleans, LA.
CF were isolated from wild type male C57BL/6 mice weighing ~25–30 g and aged 3 to 4
months as discussed in detail in Supplementary methods. Freshly isolated and up to third
passage CF were used in all experiments. At 50–70% confluency, the cells were made
quiescent by incubating in a medium containing 0.5% BSA (serum-free) for 48 h. These
growth-arrested and synchronized CF were treated with recombinant mouse TWEAK as
described in Supplementary methods.
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2.2.2. Lentiviral and adenoviral infection—Lentiviral short hairpin RNA (shRNA)
against TRAF3IP2, TWEAKR, p65 subunit of NF-κB, and c-Jun subunit of AP-1 were
purchased from Sigma-Aldrich (St. Louis, MO, USA), and are described in Supplementary
methods. Lentiviral shRNA against green fluorescent protein (GFP) served as a nontargeting shRNA, and was purchased from Santa Cruz Biotechnology, Inc. (Supplementary
Table 1). Adenoviral vectors expressing TRAF3IP2, enhanced GFP (eGFP), or silencing
siRNA against NOX4 or GFP are also described in Supplementary Table 1. Infection with
lentiviral and adenoviral vectors is detailed in Supplementary methods.
2.2.3. In vitro Detection of hydrogen peroxide by Amplex Red assay—
Quiescent CF treated with TWEAK (10 ng/ml) for 1 h were analyzed for H2O2 production
using a commercially available kit (Amplex® Red Hydrogen Peroxide/Peroxidase assay kit,
Thermo Fisher Scientific). The protocol is described in Supplementary methods. Studies
were also performed after TWEAKR or NOX4 knockdown prior to TWEAK addition for 1
h.
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2.2.4. TWEAK and TWEAKR promoter-reporter activity—A 3 kb fragment of the
5′-flanking region of the murine TWEAK gene was amplified using mouse genomic DNA
as a template by the following primers containing the restriction sites KpnI and XhoI;
Forward: 5′-GCCGGTACCAGTCTCTCAGTTCATGGTCACTTTGTAC-3′ and Reverse:
5;-GCCCTCGAGGGGGGCGGGGGGCTGTGCCTGCCTCACC-3′. The amplified 3 kb
fragment was cloned into pGL4.10[luc2] vector upstream of the luciferase gene (pGL4.10TWEAK-3 kb) and sequence verified (Supplementary Fig. 1). The 3 kb fragment of the 5′
flanking region of murine TWEAKR in pGL3-Basic vector (pGL3-TWEAKR-3 kb) is
previously described [30]. pGL4.10 and pGL3-Basic served as vector controls. CF were
transduced with lentiviral shRNA against p65, c-Jun or TRAF3IP2 (moi0.5). Twenty four
hours later, the transduced cells were transfected (2 μg) with pGL4.10-TWEAK-3 kb or
pGL3-TWEAKR-3 kb or respective empty vectors along with 100 ng of the control Renilla
luciferase vector pRL-TK using the Neon transfection system (MPK-5000, Invitrogen) with
the following parameters: pulse voltage: 1400 V, pulse width: 20 ms, pulse number: 2, and
the tip type: 10 μl. Cell viability was 89%, and the transfection efficiency was 71%. Twenty
four-hours later, cells were incubated with TWEAK (10 ng/ml) for 12 h, harvested, and
analyzed with the dual luciferase reporter assay. Data were normalized by dividing firefly
luciferase activity with that of the corresponding Renilla luciferase. The activity was
expressed as fold change after considering the data obtained with respective empty vectors
alone as 1. All plasmid preparations were endotoxin-free.
2.2.5. mRNA expression by quantitative RT-PCR (RT-qPCR)—Total RNA was
isolated from frozen LV tissues using Trizol reagent (Sigma) and 0.5 μg of RNA was reverse
transcribed into cDNA using a reverse transcription kit (Agilent Technologies). IL-1β, IL-6,
IL-18, TNF-α, TNFR1, CT-1, CXCL1, CXCL2, CXCL5, MCP-1, ICAM1, Selectin E,
MMP-13, MMP-14, TIMP-1, ANP, Collagen Iα1 and Collagen IIIα1 mRNA levels were
determined by RT-qPCR using best coverage TaqMan® probes (Supplementary Table 2).
GAPDH served as the endogenous invariant control gene. All data were normalized to
corresponding GAPDH levels and analyzed using the 2−ΔΔCt method.
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2.2.6. Immunoblotting and ELISA—Preparation of whole cell lysates, membrane
extracts, immunoblotting, detection of the immuno-reactive bands by enhanced
chemiluminescence (ECL Plus; GE Healthcare), and semi-quantification by densitometry
were all described previously [26,29,31–33]. Secreted IL-1β, TNF-α and MCP-1 levels were
quantified by ELISA using equal amounts of culture supernatants. The antibodies used in
immunoblotting and the ELISA kits are listed in Supplementary Tables 3 and 4.
2.2.7. Immunofluorescence—Expression and localization of TRAF3IP2 and
TWEAKR were analyzed by immunofluorescence using the antibodies described under
immunoblotting/immunofluorescence in Supplementary Table 3.
2.2.8. Collagen secretion by hydroxyproline assay—Total collagen content in
equal amounts of culture supernatants was analyzed as previously described [34]. In brief,
culture supernatants after 24 h TWEAK treatment were digested with 6 N hydrochloric acid
for 12 h at 110 °C, vacuum dried, resuspended in citrate-acetate buffer, and a colored
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reaction was performed by adding isopropyl alcohol, chloramine T, and Ehrlich’s reagent.
The samples were then incubated at 25 °C for 18 h, and intensity of the red color was
measured at 558 nm. A standard curve was generated using known concentrations of
hydroxyproline. After calculating hydroxyproline content in the unknown samples, the
amount of collagen was calculated by multiplying hydroxyproline content by a factor of 8.2.
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2.2.9. Cell proliferation—The effects of TWEAK on CF proliferation were analyzed
according to manufacturer’s protocol using the CyQUANT® assay (Invitrogen) [35].
Briefly, second-passage CF were plated at 2000 cells per well into 96-well clear bottom,
black-sided plates (VWR Scientific Products, West Chester, PA), and allowed to attach
overnight. After 24 h, the cells were fed with serum-free medium containing 0.5% BSA and
incubated for an additional 24 h. Cells were then continuously stimulated with TWEAK (10
ng/ml) in serum-free medium for 24 h. After removing the medium, the plates were frozen at
−80 °C for 2 h before assay. Plates were then thawed, stained with CyQUANT® GR dye
according to manufacturer’s protocol, and assayed on a FLX800 microplate fluorescence
reader (Bio-Tek Instruments, Winooski, VT) using 485/20 excitation and 528/20 emission
filters, and analyzed using KC4 software (Bio-Tek). Proliferation assays were carried out 6
times. To determine the role of TWEAKR or TRAF3IP2 in TWEAK-induced CF
proliferation, CF were plated in complete medium, and after 24 h, cell were infected with
lentiviral shRNA against TWEAKR or TRAF3IP2 (moi0.5). One hour later, the medium
with virus was changed to medium containing 0.5% BSA for an additional 24 h. The cells
were then incubated with TWEAK as described above. Lentiviral shRNA against eGFP at a
similar moi and duration served as a control.
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2.2.10. Cell migration—CF migration was quantified as described previously using
BioCoat™ Matrigel™ migration chambers and 8.0-μm pore polyethylene terephthalate
membranes with a thin layer of Matrigel™ basement membrane matrix [35]. Cultured CF
were trypsinized and suspended in RPMI + ITS 1×), and 1 ml containing 2.0 × 105 cells was
layered on the coated insert filters. Cells were stimulated with TWEAK (10 ng/ml). The
lower chamber contained medium with 10% serum. Plates were incubated at 37 °C for 12 h.
The membranes were washed with PBS, and non-invading cells on the upper surface were
removed using cotton swabs. CF invading into and through the Matrigel™ matrix were
quantified by MTT assay. Numbers of CF migrating in response to TWEAK were
normalized to those of untreated cells and expressed as fold change from untreated.
Migration assays were carried out 6 times. To determine the role of TWEAKR or TRAF3IP2
in TWEAK-induced CF proliferation, CF infected with lentiviral TWEAKR or TRAF3IP2
(moi0.5 for 48) were layered on the coated insert filters and treated with TWEAK (10 ng/ml)
for 12 h. Lentiviral shRNA against eGFP at a similar moi and duration served as a control.
2.2.11. Cell death detection by ELISA—After 48 h incubation in DMEM containing
0.5% BSA, CFs were treated with TWEAK (0.1–1000 ng/ml) 24 h. Cells were harvested
and analyzed for mono- and oligo-nucleosomes in the cytoplasmic fraction of cell lysates by
a cell death detection ELISA as detailed in Supplementary Methods. H2O2 (100 μM) serves
as a positive control.
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In vivo studies
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2.3.1. Animals—Male wild type (WT) C57Bl/6 mice were purchased from the Jackson
Laboratory (Bar Harbor, ME). The TRAF3IP2-knockout mice (TRAF3IP2-KO) on C57Bl/6
background were previously described [26]. All mice used in the study were male, aged 3–4
months and weighed ~25–30 g. However, in TUNEL assay, ovaries from 3 month old naïve
female C57Bl/6 mice were used as a positive control to detect cells undergoing apoptosis.
The TRAF3IP2-KO mice exhibited no basal phenotypic abnormalities. We had 4 groups of 5
mice each: Group 1, WT mice infused with physiological saline, Group 2: WT mice infused
with recombinant TWEAK, Group 3: TRAF3IP2-KO mice infused with physiological
saline, and Group 4: TRAF3IP2-KO mice infused with recombinant TWEAK. Both WT and
TRAF3IP2-KO mice were administered with recombinant mouse TWEAK (10 μg in
physiological saline/kg body weight/day) for 7 days using subcutaneously implanted
osmotic minipumps. Control animals were implanted with sterile salinefilled pumps. The
dose of TWEAK was chosen based on previous published reports, where recombinant
TWEAK was administered to mice between 2 and 200 micrograms, either as a single bolus
or repeatedly, and either intraperitoneally or continuously via subcutaneously implanted
osmotic minipumps for up to 14 days [36,37]. At the end of the 7-day study period, systolic
blood pressure (SBP) was measured by tailcuff plethysmography. Myocardial function was
analyzed by 2D echocardiography.
2.3.2. Systolic blood pressure (SBP) by tail-cuff plethysmography—Prior to
initiation of study, animals were trained for SBP measurement using a tail-cuff method
without anesthesia (CODA Noninvasive Blood Pressure System, Kent Scientific, Torrington,
CT). SBP was also measured at 1, 2, and 7 days post-TWEAK administration.
2.3.3. Echocardiography—Left ventricular (LV) function was analyzed by 2D
echocardiography (Acuson 128XP/10) as described before [31]. We measured LV Posterior
Wall thickness at end-systole (LVPWs), LV Posterior Wall thickness at end-diastole
(LVPWd), LV Internal Dimension at end-systole (LVIDs), LV Internal Dimension at enddiastole (LVIDd), LV Volume at end-systole (LVVols) and Ejection Fraction (EF).
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2.3.4. Myocardial hypertrophy—After recording body weights, mice were deeply
anesthetized with ketamine:xylazine (9:1; 0.1 ml, IM). After thoracotomy, blood was drawn
by heart puncture, perfused with physiological saline, and hearts removed. After recording
heart weights, LV was separated, cut into three pieces, and used for histology and
biochemical/molecular analysis. Myocardial hypertrophy was determined by three different
methods: heart weight to body weight ratios, quantification of cardiomyocyte cross-sectional
area by WGA staining of fixed tissue sections (Supplementary methods and Supplementary
Table 3), and fetal gene (ANP) expression by RT-qPCR. Hypertrophic response was also
analyzed by normalizing heart weights to tibia length. To measure tibia length, hind limbs
were incubated in 1 M NaOH for 5 h at 37 °C with occasional agitation to digest skin, fat,
and muscle tissue. After digestion, the tibia was collected, rinsed in physiological saline,
dried on a paper towel, and the length measured using a digital caliper.
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2.3.5. Cardiac fibrosis—Cardiac fibrosis was analyzed by three different methods: (i)
Masson’s trichrome staining using 6 μM-thick sections, (ii) collagens Ia1, collagen IIIa1,
and fibronectin mRNA expression by RT-qPCR, and (iii) collagens Ia1, collagen IIIa1, and
fibronectin protein expression by immunoblotting, and are described in Supplementary
Methods. Measurement of histological myocardial fibrosis following Masson’s trichrome
staining was performed by the NIH Image J software, and presented as percent area
occupied by collagens.
2.3.6. Terminal transferase-mediated dUTP-biotin nick end-labeling (TUNEL)
assay—In situ detection of DNA stand breaks was analyzed by TUNEL assays using the
ApopTag® Peroxidase In Situ Apoptosis Detection Kit. The assays were performed
essentially as described by the manufacturer. Spleen, testis and ovary from naïve WT mice
were used as positive controls.
2.4.

Statistical analysis

VA Author Manuscript

All data are expressed as mean ± SE. Statistical significance was determined by one-way
analysis of variance followed by Tukey’s posthoc test (GraphPad Prism software, San Diego,
CA). Prior to performing one-way analysis of variance, normality of distribution and
equality of variance were considered. In addition, all 4 groups contained equal number of
animals. Differences are considered significant if the P value is less than or equal to 0.05. A
power analysis was performed prior to initiating the study to ensure that type II errors are
unlikely. In Fig. 6, the panel describing LVPWd in WT mice infused with TWEAK, the
Grubbs’ method in GraphPad identified an outlier. Therefore, the data in that specific panel
represent 4 animals. Further, though a representative immunoblot is shown in the main
figures, changes in protein/phosphorylation levels from three to four independent
experiments were semi-quantified by densitometry, and are shown as ratios and fold changes
from untreated or respective controls at the bottom or side of respective panels.

3.

Results

3.1. TWEAK upregulates TRAF3IP2 expression in cultured cardiac fibroblasts (CF) in part
via oxidative stress

VA Author Manuscript

The results in Fig. 1A show that TRAF3IP2 is expressed at low basal levels in CF, and
treatment with TWEAK for 2 h upregulated its expression in a dose-dependent manner, with
peak levels detected ~10 ng/ml. At higher concentrations, TWEAK did not further increase
TRAF3IP2 expression, but in fact suppressed its levels. At higher levels, TWEAK reduced
fibroblast viability, as evidenced by increased levels of monoand oligonucleosomal
fragmented DNA in the cytoplasmic extracts, as well as active (cleaved) caspase-3 (Fig. 1B),
suggesting that at higher concentrations TWEAK affects CF survival. Therefore, TWEAK
was used at 10 ng/ml in all subsequent experiments. At this concentration, TWEAK
upregulated TRAF3IP2 expression in a time-dependent manner with peak levels detected
after 2 h treatment (Fig. 1C). Interestingly, even after 24 h, TRAF3IP2 levels remained
above basal levels (Fig. 1C), suggesting persistent induction. Consistent with
immunoblotting data, immunofluorescence revealed low levels of TRAF3IP2 at basal
conditions, localized predominantly in cytoplasm (Fig. 1D). However, treatment with
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TWEAK increased TRAF3IP2 expression and showed cytoplasmic, perinuclear and nuclear
localization (Fig. 1D), suggesting that TWEAK treatment promotes TRAF3IP2 nuclear
localization. Immunoblotting using cytoplasmic and nuclear extracts confirmed these results
(Fig. 1E). Since TWEAK signals mainly via TWEAKR, we next investigated whether
silencing or neutralizing TWEAKR blunts TWEAK-induced TRAF3IP2 expression. The
results in Fig. 1F show that silencing TWEAKR by lentiviral shRNA and preincubation with
ITEM-4, an anti-TWEAKR neutralizing antibody, each inhibited TWEAK-induced
TRAF3IP2 upregulation (knockdown of TWEAKR was confirmed by immunoblotting and
is shown on the right in panel G). gp130 served as an off target, and its expression was not
affected by the shRNA directed against TWEAKR (Fig. 1G). Since TRAF3IP2 is a redoxsensitive adapter molecule [33], we next investigated whether TWEAK-induced TRAF3IP2
expression is regulated by oxidative stress. Indeed, TWEAK significantly increased H2O2
generation (Fig. 1H), and silencing TWEAKR and NOX4 each attenuated its production and
TRAF3IP2 induction (Fig. 1I), indicating that TWEAK upregulates TRAF3IP2 expression
in CF via TWEAKR and oxidative stress (Fig. 1).
3.2.

TRAF3IP2 mediates TWEAK-induced p38 MAPK, NF-κB and AP-1 activation in CF
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Persistent inflammation, even at a low grade, promotes cardiac fibrosis [38]. The mitogenactivated protein kinase p38 and the redoxsensitive nuclear transcription factors NF-κB and
AP-1 not only play a role in signal transduction of various inflammatory cytokines, but also
regulate their induction. Since TRAF3IP2 is an upstream regulator of p38 MAPK, NF-κB,
and AP-1 [29,32], we investigated whether TWEAK regulates their activation in CF via
TRAF3IP2. Indeed, TWEAK induced p38 MAPK activation in CF in a time-dependent
manner as evidenced by an increase in its Thr180/Tyr182 phosphorylated form (Fig. 2A), and
this effect was markedly suppressed by TRAF3IP2 knockdown or pretreatment with the p38
MAPK-specific inhibitor SB 239063 (Fig. 2B; ~70% knockdown of TRAF3IP2 by lentiviral
shRNA as shown on the right). Similarly, TWEAK induced NF-κB activation in a timedependent manner (Fig. 2C), as evidenced by an increase in Ser536-phophorylated p65, an
effect also inhibited by TRAF3IP2 knockdown (Fig. 2D) and SB 239063 (Fig. 2D).
TWEAK also induced JNK activation, as evidenced by a time-dependent increase in
Thr183/Tyr185-phopsorylated form (Fig. 2E, upper panel). Further, TWEAK induced Ser63
phosphorylation of c-Jun, one of the subunits of AP-1 and a substrate of JNK, indicating its
activation (Fig. 2E, lower panels). Importantly, silencing TRAF3IP2 and pretreatment with
the JNK inhibitor SP600125 attenuated JNK activation and c-Jun phosphorylation (Fig. 2E).
These results indicate that TWEAK induces p38 MAPK, NF-κB, and JNK/AP-1 activation
in CF in part via TRAF3IP2 (Fig. 2).
3.3. TRAF3IP2 and its downstream signaling intermediates mediate TWEAK
autoregulation and TWEAKR upregulation in CF
The 5′-regulatory regions of TWEAK and TWEAKR contain binding sites for several
putative transcription factors, including NF-κB for TWEAK [21] and AP-1 for TWEAKR
[30]. Since TRAF3IP2 is an upstream regulator of both transcription factors [24,25], we next
investigated whether TRAF3IP2 mediates TWEAK-induced TWEAK and its receptor
expression. The results in Fig. 3A show that CF express low levels of TWEAK at basal
conditions, and treatment with TWEAK rapidly and significantly upregulated its expression
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in a time dependent manner, with increased levels detected for up to 2 h. This increased
expression represents, at least initially, both exogenous and endogenous TWEAK.
Importantly, silencing TRAF3IP2 blunted TWEAK auto-regulation (Fig. 3A). Similarly,
TWEAKR expression was detected at low basal levels, and treatment with TWEAK
upregulated its expression in a time-dependent manner, and in part via TRAF3IP2 (Fig. 3B).
Confirming the immunoblotting results, immunofluorescence revealed low expression of
TWEAKR in CF at basal conditions, and its increased levels after 2 h treatment with
TWEAK, with both membrane and cytoplasmic localization, and its reduced expression
following TRAF3IP2 knockdown (Fig. 3C). Further, silencing TRAF3IP2 or its downstream
signaling intermediates NF-κB and AP-1, or pharmacological inhibition of p38MAPK,
markedly inhibited TWEAK autoregulation and TWEAKR upregulation (Fig. 3D; p65 and
c-Jun knockdown is shown on the right in panel E). Promoter reporter assays demonstrated
that TWEAK induces transcription of both TWEAK and its receptor in CF. By analyzing
promoter regions 3 kb upstream of TWEAK and TWEAKR for putative transcription factor
binding sites using the PROMO (Prediction of transcription factor binding sites) program
[39,40], we identified nine NF-κB and five AP-1 potential binding sites in TWEAK
promoter (Supplementary Fig. 1). Similarly, we identified seven NF-κB and five AP-1
potential binding sites in TWEAKR promoter. Importantly, silencing TRAF3IP2, p65 or cJun attenuated the promoter-reporter activities of both TWEAK and TWEAKR (Fig. 3G),
suggesting that TRAF3IP2 activates their transcription possibly via a NF-κB- and AP-1dependent pathway. Together, these results demonstrate that TRAF3IP2 plays a critical role
in TWEAK/TWEAKR induction in CF. To further demonstrate its critical role, we
overexpressed TRAF3IP2 by adenoviral transduction, and investigated whether
overexpression of TRAF3IP2 by itself induces TWEAK/TWEAKR expression. Indeed,
ectopic expression of TRAF3IP2 at various multiplicities of infection (moi) increased
TRAF3IP2 expression in a dose-dependent manner, with peak levels detected at a moi of 50
(Fig. 3H). However, ectopic expression of eGFP, used as a control, failed to modulate
TRAF3IP2 expression (Fig. 3H). Importantly, forced expression of TRAF3IP2, by itself,
induced TWEAK and TWEAKR expression (Fig. 3I). These results demonstrate a positive
feedback regulation between TRAF3IP2 and TWEAK/TWEAKR signaling (Fig. 3).
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3.4.

TRAF3IP2 regulates TWEAK-induced proinflammatory responses in CF
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Several inflammatory mediators are p38 MAPK, NF-κB and/or AP-1 responsive genes.
Since TWEAK induced TRAF3IP2-dependent p38 MAPK, NF-κB and AP-1 activation in
CF (Fig. 2), we next investigated whether TWEAK induces proinflammatory responses in
CF in part via TRAF3IP2. Indeed, TWEAK enhanced the mRNA expression of multiple
inflammatory mediators, including cytokines (IL-1β, IL-6, IL-18, TNF-α), cytokine
receptors (TNFR1), growth factors (CT-1), chemokines (CXCL1, CXCL2, CXCL5, MCP-1)
and adhesion molecules (ICAM1, Selectin E), an effect markedly inhibited by TRAF3IP2
knockdown (Fig. 4A). Silencing of TRAF3IP2 also inhibited TWEAK-induced IL-1β, TNFα and MCP-1 secretion (Fig. 4B). Confirming reduced mRNA expression (Fig. 4A),
silencing TRAF3IP2 also inhibited ICAM1, VCAM1 and Selectin E protein levels (Fig. 4C).
These results indicate that TRAF3IP2 is a critical signaling intermediate in TWEAKinduced proinflammatory responses in CF (Fig. 4).
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3.5. TRAF3IP2 mediates TWEAK-induced collagen expression, MMP activation, and CF
proliferation and migration
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At basal conditions, a fine balance between deposition and proteolytic enzyme-mediated
degradation of extracellular matrix proteins (e.g., fibrillar collagens) plays a vital role in
maintaining normal myocardial structure and function. However, when ECM deposition
exceeds degradation, and if the process persists, fibrosis ensues resulting in adverse cardiac
remodeling, contractile dysfunction and HF development [41]. Since fibroblasts are one of
the major cell types responsible for collagen synthesis, secretion, and deposition in the heart,
and as COL1A1 and COL3A1 are redox-sensitive and NF-κB- and/or AP-1-responsive
genes, we hypothesized that TRAF3IP2 mediates TWEAK-induced collagen expression in
CF. Indeed, TWEAK upregulated collagens Iα1 and IIIα1 expression in a time-dependent
manner (Fig. 5A), and in TRAF3IP2-dependent manner (Fig. 5B). Further, TWEAK
promoted collagen secretion in part via TRAF3IP2 (Fig. 5C). Collagen expression and
degradation are regulated by MMPs and their tissue inhibitors TIMPs. Fibrillar collagens are
initially degraded by collagenases followed by gelatinases. Therefore, we analyzed
MMP-13, a major collagenase in mice, and its activator MMP-14 or MT1-MMP. The data
show that TWEAK induced mRNA and protein expression of both MMPs 13 and 14 in CF
in a TRAF3IP2-dependent manner (Fig. 5D). Further, TWEAK also induced TIMP-1
expression in a TRAF3IP2-dependent manner (Fig. 5D). CF express the glatinases MMPs 2
and 9, and both MMPs are NF-κB and/or AP-1 responsive genes. Therefore, we next
analyzed activation of MMPs 2 and 9 by immunoblotting using antibodies that detect both
pro and active forms. The data in Fig. 5E and F show that TWEAK increases activation of
both MMPs as evidenced by increased levels of respective active forms, and their significant
inhibition by TRAF3IP2 knockdown. Since increased fibroblast proliferation and migration
are two major players in cardiac fibrosis [38,41], we hypothesized that TRAF3IP2 mediates
TWEAK-induced CF proliferation and migration. Indeed, TWEAK significantly increased
CF proliferation (Fig. 5G) and migration (Fig. 5H), and silencing TRAF3IP2 or TWEAKR
blunted its mitogenic and migratory effects. These results indicate that targeting TRAF3IP2
blunts TWEAKinduced pro-fibrotic responses in CF (Fig. 5).
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3.6. TRAF3IP2 gene ablation blunts TWEAK-induced myocardial hypertrophy and
contractile dysfunction in a blood pressure-independent manner
Since silencing TRAF3IP2 blunted TWEAK-induced proinflammatory, pro-mitogenic and
pro-migratory effects in cultured CF (Figs. 1–5), we next hypothesized that targeting
TRAF3IP2 ameliorates TWEAK-induced cardiac fibrosis and adverse remodeling in vivo.
Both WT and homozygous TRAF3IP2-KO mice were continuously infused with
recombinant mouse TWEAK for 7 days using subcutaneously implanted osmotic
minipumps (Fig. 6A). Tail-cuff plethysmography demonstrated a significant time-dependent
increase in SBP in WT mice infused with TWEAK, but not saline used as a solvent control
(Fig. 6B). Interestingly, TWEAK infusion increased SBP to a similar extent in the
TRAF3IP2-KO mice (Fig. 6B). Further, no changes in body weights were detected in WT
and TRAF3IP2-KO mice infused with TWEAK for 7 days (Fig. 6C). However, TWEAK
infusion for 7 days resulted in myocardial hypertrophy in WT mice, as evidenced by
increased heart weight to body weight ratios (Fig. 6D). Heart weights normalized to tibia
length also showed a similar trend (data not shown). Notably, its pro-hypertrophic effects
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were blunted in the TRAF3IP2-KO mice (Fig. 6D). Increased cardiomyocyte cross-sectional
area (Fig. 6E and F) and increased expression of fetal genes ANF and β-MHC (Fig. 6G)
confirmed the pro-hypertrophic responses of TWEAK in the WT mice. Further,
echocardiography revealed contractile dysfunction in TWEAK-infused WT, but not
TRAF3IP2-KO mice, as evidenced by significant increases in LVPWs and LVPWd), and
decreased LVIDs and LVIDd, LVVols and EF (Fig. 6H). Importantly, no cell death was
detected in the hearts of TWEAK-infused WT or TRAF3IP2-KO mice (Supplementary Fig.
2). These results indicate that TRAF3IP2 gene ablation blunts TWEAK-induced adverse
cardiac remodeling and contractile dysfunction, independent of increases in SBP (Fig. 6).
3.7.

TRAF3IP2 gene ablation blunts TWEAK-induced cardiac fibrosis
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Adverse cardiac remodeling is characterized by increased deposition of extracellular matrix
proteins, including fibrillar collagens and fibronectin, in the heart [38,41]. The results show
that while the baseline values of fibrosis (percent area occupied by collagens) are similar
between WT and TRAF3IP-KO mice (data not shown), continuous infusion of TWEAK for
7 days (Fig. 7A) significantly increased interstitial fibrosis in hearts from the WT, but not
TRAF3IP2-KO, mice (Fig. 7B). Further, TWEAK infusion increased mRNA (Fig. 7C) and
protein expression of both fibrillar collagens I and III, as well as fibronectin, in the WT
mouse heart (Fig. 7D; densitometric analysis is summarized in panel E). Importantly,
TRAF3IP2 gene deletion blunted these TWEAK-induced profibrotic responses (Fig. 7B–E),
indicating its critical role in TWEAK-induced cardiac fibrosis (Fig. 7).
3.8. TRAF3IP2 gene ablation blunts TWEAK-induced p38 MAPK, NF-κB and AP-1
activation, and inflammatory responses in the heart
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Our in vitro results showed that TWEAK stimulates ROS generation (Fig. 1), TRAF3IP2
upregulation (Fig. 1), TRAF3IP2-dependent p38 MAPK, NF-κB and AP-1 activation (Fig.
2), and TRAF3IP2-dependent proinflammatory cytokine expression in cultured CF (Fig. 4).
Of note, several of these inflammatory mediators not only exert pro-hypertrophic and profibrotic responses, but also induce contractile dysfunction [42]. In fact, recapitulating the in
vitro data, TWEAK infusion for 7 days (Fig. 8A) increased oxidative stress in the hearts of
WT mice, as evidenced by a significant increase in lipid peroxides (Fig. 8B), a surrogate
marker of oxidative stress. Further, TWEAK infusion upregulated TRAF3IP2 expression
(Fig. 8C), and p38 MAPK, NF-κB, and AP-1 activation in the hearts of WT mice.
Importantly, TRAF3IP2 gene ablation blunted, but not abrogated, these responses (Fig. 8C).
Furthermore, TRAF3IP2 deletion inhibited TWEAK-induced TWEAK and TWEAKR
expression, and the induction of multiple inflammatory mediators, including IL-18, TNF-α,
TNFR1, MCP-1, ICAM1 and iNOS in the heart (Fig. 8C; summarized densitometric
analyses are shown at the bottom in panel D). These results demonstrate the critical role of
TRAF3IP2 in TWEAK-induced myocardial inflammation (Fig. 8).

4.

Discussion
The major findings of this study are: TWEAK upregulates TRAF3IP2 expression in cultured
cardiac fibroblasts. TWEAK also promotes its nuclear localization. Silencing TRAF3IP2
inhibits TWEAK-induced p38 MAPK, NF-κB and AP-1 activation, its own and that of its
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receptor (TWEAKR) expression, various other inflammatory mediators, collagen expression
and release, and induction of MMPs that exert collagenolytic activity. Importantly, silencing
TRAF3IP2 inhibits TWEAK-induced CF proliferation and migration. Further supporting its
critical role, forced expression of TRAF3IP2, by itself, upregulates TWEAK and its receptor
expression, suggesting a feed-forward loop between TWEAK and TRAF3IP2 in CF.
Recapitulating the in vitro results, continuous infusion of TWEAK for 7 days increases SBP,
upregulates TRAF3IP2 expression, activates p38 MAPK, NF-κB and AP-1, enhances the
expression of various cytokines, chemokines, and adhesion molecules, and increases
collagen expression and interstitial fibrosis in hearts from wild type mice. These
proinflammatory and pro-fibrotic changes occur in conjunction with myocardial hypertrophy
and contractile dysfunction. Importantly, TRAF3IP2 gene ablation ameliorates these adverse
cardiac changes, independent of increases in SBP. These results indicate that TRAF3IP2
plays a causal role, and thus a potential therapeutic target, in inflammatory cardiac diseases
(Fig. 9).
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TWEAK and its receptor are expressed at low basal levels and play a role in normal
development and immune regulation. However, their increased expression for brief periods
following injury or infection contributes to tissue repair and resolution of inflammation [12].
However, when expressed at high levels and for prolonged periods, this ligand/receptor pair
plays a deleterious role in various models of inflammation, including myocardial
inflammation, injury and HF development. In many inflammatory diseases, including that of
the heart, the signal transduction pathways activated by TWEAK/TWEAKR culminate in
NF-κB and AP-1 activation, involving one of the TRAF family members [11]. For example,
the interaction between TWEAKR and TRAF6 has been shown to activate NF-κB via a
canonical or a noncanonical pathway involving the IKK signalosome that contains the
catalytic subunits IKKα and IKKβ, and the regulatory subunit IKKγ or NEMO. Interactions
between TWEAKR and TRAF6 also activate AP-1, in part via the MAP kinase JNK. In turn,
NF-κB and AP-1, either alone or in cooperation, can transcriptionally upregulate the
expression of various genes involved in inflammation, proliferation, survival, or death [11].
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Persistent activation of MAP kinases plays a pathological role in cardiac diseases [43]. Our
data show that TWEAK induces p38 MAPK activation in part via TRAF3IP2, and targeting
its activation by a pharmacological inhibitor attenuates NF-κB activation, suggesting a
crosstalk between p38 MAPK and NF-κB in amplifying TWEAK-induced inflammatory
signaling in CF. Previously, we reported that targeting p38 MAPK also inhibited IL-17induced AP-1 activation in human CF, suggesting that targeting p38 MAPK can inhibit
TWEAK-induced activation of both NF-κB and AP-1. Though we have not investigated the
underlying molecular mechanisms involved in TWEAK-induced TRAF3IP2-dependent p38
MAPK activation, it is plausible that oxidative stress and interactions between TWEAKR
and members of the TRAF family might have contributed to its activation. For example,
TRAF3IP2 might have induced p38 MAPK activation via TRAF6/TAK1/ROS or
TRAF6/MKK (Mitogen-activated Protein Kinase Kinase)3/6. In fact, our data show that
TWEAK induces NOX4-dependent ROS generation in CF. More importantly, targeting
TRAF3IP2 suppresses p38 MAPK-, NF-κB- and/or AP-1-responsive inflammatory gene
expression, including IL-1β, IL-6, IL-18, TNF-α, CT-1, CXCL1, CXCL2, CXCL5, MCP-1,
ICAM1, and Selectin A.
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Previously, TWEAK was shown to stimulate collagen synthesis and proliferation of rat CF
[6]. Here we demonstrated that TWEAK upregulates collagen expression and secretion by
mouse CF in a TRAF3IP2- dependent manner. Interestingly, though TWEAK enhanced
collagen expression, it also promoted induction and activation of MMPs with collagenolytic
activity. For example, TWEAK upregulated the expression of MMP-13, the predominant
collagenase in mice. It also upregulated the expression of MMP-14, a membrane type 1
MMP (MT1-MMP), that plays a role in MMP-13 activation by processing pro-MMP-13 to a
fully active form [44]. Interestingly, TWEAK also induced TIMP-1 expression. It also
induced activation of the gelatinases MMP-2 and MMP-9 that are known to further degrade
denatured collagens, indicating that TWEAK promotes both synthesis and degradation of
collagens, with a net positive effect on synthesis, resulting ultimately in increased fibrosis. In
fact, TWEAK infusion for 7 days induced interstitial fibrosis in WT mouse heart, and its
significant inhibition in TRAF3IP2-KO mice. Of note, MMPs 2, 9, 13 and 14, and TIMP-1
are all NF-κB and/or AP-1 responsive genes. Targeting TRAF3IP2 also inhibited TWEAKinduced CF migration and proliferation, further supporting a causal role for TRAF3IP2 in
TWEAK-induced proinflammatory and pro-fibrotic responses in CF.
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Interestingly, some of the proinflammatory mediators induced by TRAF3IP2 also regulate
TRAF3IP2 expression. For example, IL-1, TNF-α and LPS have all been shown to
upregulate TRAF3IP2 expression in human lung epithelial cells [45]. We have previously
demonstrated that IL-18, which signals via the cytoplasmic adapter molecule MyD88,
promotes CF migration and differentiation in part via TRAF3IP2 [46], indicating a potential
positive feedback loop between inflammatory mediators and TRAF3IP2 in perpetuating
inflammation. It also suggests that TRAF3IP2 could play a role in the signal transduction of
cytokines other than IL-17 either directly or through TIR-signaling intermediates. Though
our data show a critical role of TRAF3IP2 in TWEAK/TWEAKR signaling, it is not known
whether a physical interaction between TRAF3IP2 and TWEAKR is necessary to activate
downstream proinflammatory signaling, such as those reported for TRAF3IP2 and IL-17R
[24,25,47]. Interestingly, both TRAF3IP2 and TWEAKR contain TRAF-interacting
domains. For example, similar to TWEAKR binding to various TRAFs via a –PIEET-motif
at the C-terminus cytoplasmic tail [11,12], TRAF3IP2 is known to bind various TRAFs via
two TRAF-interacting motifs [48]. Therefore, it is plausible that TRAF3IP2 might
physically associate with TWEAKR by forming complexes involving TRAF proteins,
considering that TRAF proteins oligomerize through their RING domain interaction. Our
future studies will determine this possibility.
Originally, TRAF3IP2 has been shown to localize in cytoplasm [24,25]. However, in 2012,
we reported its nuclear localization in Angiotensin II-treated isolated cardiomyocytes [26].
Here, as reported in cardiomyocytes, TWEAK promoted TRAF3IP2 nuclear localization in
CF. Though we have not investigated the significance of its nuclear localization, a recent
report also demonstrated TRAF3IP2 nuclear localization in IL-17-treated airway epithelial
cells [49]. Those authors further demonstrated that the translocated TRAF3IP2
transcriptionally upregulated beta-defensin B4 (DEFB4) [49], an IL-17-responsive gene,
induced locally by inflammation, by binding a large portion of its promoter region
encompassing several NF-κB binding sites. However, mutating those NF-κB-binding sites
failed to modulate DEF4B transcription [49], suggesting that though TRAF3IP2 is an
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upstream regulator of NF-κB, its effects on transcription of some of the IL-17-responsive
genes are not NF-κB dependent. Together, these reports demonstrate that TRAF3IP2 not
only resides in cytoplasm and functions as an E3-ubiquitin ligase [47], it translocates to the
nucleus to transcriptionally upregulate some IL-17-responsive genes via mechanisms not
fully understood. Since members of the IKK complex shuttle between cytoplasm and
nucleus, and as TRAF3IP2 is known to bind all members of the IKK signalosome [24], we
hypothesize that its physical interaction with IKKs is one of the mechanisms responsible for
its nuclear translocation. Our future studies will investigate this hypothesis. In addition, we
will also determine whether nuclear TRAF3IP2 transcriptionally upregulates genes involved
in inflammation and fibrosis in CF treated with TWEAK and other pro-fibrotic mediators,
including Angiotensin II [26].
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Recapitulating the in vitro results, our in vivo results show that infusion of TWEAK for 7
days increases SBP, contractile dysfunction, TRAF3IP2 expression, p38 MAPK, NF-κB,
and AP-1 activation, cytokine and collagen expression, and interstitial fibrosis in a WT
mouse heart. Importantly, genetic ablation of TRAF3IP2 inhibited these deleterious effects,
without affecting increases in SBP. Of note, we previously reported that TRAF3IP2 deletion
blunts angiotensin II- and aldosteroneinduced adverse myocardial remodeling without
modulating increases in SBP [26,50]. In those models, lack of TRAF3IP2 blunted oxidative
stress and expression of various inflammatory markers, indicating that the effects of lack of
TRAF3IP2 on hypertrophy and fibrosis are blood pressure independent, and likely due to
suppression of oxidative stress and inflammation. For example, low doses of spironolactone,
a mineralocorticoid receptor antagonist, was previously reported to improve diastolic
dysfunction without lowering blood pressure in transgenic (mRen2)27 [TG(mRen2)27] rats
that are severely hypertensive and express high levels of tissue angiotensin II and plasma
aldosterone [51], indicating a disconnect between therapeutic improvements in cardiac
function and structure and blood pressure. Thus, it is not entirely surprising that TRAF3IP2
deletion blunted adverse remodeling in the absence of improvement in blood pressure in
TWEAK-infused mice, and that this improvement in remodeling is likely due to reductions
in oxidative stress and inflammation. These results also indicate that TRAF3IP2 is a critical
player in TWEAK-induced adverse cardiac remodeling and contractile dysfunction, and thus
a potential therapeutic target.
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TWEAK has been targeted in various autoimmune and inflammatory diseases like
rheumatoid arthritis (RA) and lupus nephritis. In a phase I clinical trial using RA subjects
(ClinicalTrials.gov identifier: NCT00771329), Wisniacki, et al. reported that a single dose of
a TWEAK-blocking monoclonal antibody (BIIB023) suppressed serum levels of soluble
TWEAK for several days. In those subjects BIIB023 showed a favorable safety and
tolerability profile [52]. However, in a phase II clinical trial (ClinicalTrials.gov Identifier:
NCT01499355), the same antibody failed to show improvements in subjects with lupus
nephritis, and therefore had to be discontinued. In an ongoing independent phase I clinical
trial (ClinicalTrials.gov Identifier: NCT02628795), it will be determined whether targeting
TWEAK signaling will restore muscle and mobility in subjects with end-stage osteoarthritis,
a chronic inflammatory disease. These clinical trials suggest that targeting TWEAK/
TWEAKR or their signaling is beneficial in slowing the progression of some autoimmune
and inflammatory diseases. Since TRAF3IP2 is a critical player in various autoimmune and
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inflammatory diseases, and TWEAK-induced inflammatory signaling and adverse cardiac
remodeling are markedly inhibited by TRAF3IP2 deletion, we hypothesize that TRAF3IP2
serves as a potential novel therapeutic target in inflammatory cardiac diseases.
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A limitation of the study is that though TRAF3IP2 deletion significantly reduced TWEAKmediated inflammatory response and fibrosis, it did not totally reverse TWEAK’ effects on
these critical phenomena, indicating TRAF3IP2-independent effects of TWEAK on adverse
cardiac remodeling and contractile dysfunction. In fact, using bioinformatics, Bhattacharjee,
et al. reported activation and interaction of diverse signaling pathways in various cell types
treated with TWEAK [11], a majority of which involve interaction with one or more
members of the TRAF family, ultimately resulting in the activation of NF-κB and AP-1.
Interestingly, TRAF3IP2 also interacts with these TRAFs in a cell type and contextdependent manner, resulting in activation of NF-κB and AP-1, and activation of downstream
inflammatory and pro-fibrotic pathways. Because of interactions with members of TRAF
family and activation of NF-κB and AP-1, we strongly believe in a critical role for
TRAF3IP2 in TWEAK signaling, and its potential as a therapeutic target in TWEAKassociated pathologies. Another limitation of the study is that no diastolic parameters were
analyzed in TWEAK-infused animals as fibrosis is known to be associated with diastolic
dysfunction.
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Act1

NF-kappa B Activator 1

ANP

atrial natriuretic peptide

AP-1

activator protein-1

CCL

C-C Motif Chemokine Ligand

CD

Cluster of Differentiation

CF

cardiac fibroblasts

CIKS

Connection to IKK and SAPK/JNK

ColIα1

collagen Iα1
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ColIIIα1

collagen IIIα1

CT1

Cardiotrophin 1

ColIα1

Collagen Type I Alpha 1 chain

CTGF

connective tissue growth factor

CXCL

C-X-C Motif Chemokine Ligand

DMEM

Dulbecco’s Modified Eagle Medium

DMSO

dimethyl sulfoxide

E3

ubiquitin-protein isopeptide ligase

ECM

extracellular matrix

EF

ejection fraction

eGFP

enhanced green fluorescent protein

ELISA

Enzyme Linked Immunosorbent Assay

Fn14

Fibroblast Growth Factor-Inducible Immediate-Early Response
Protein 14

GAPDH

Glyceraldehyde 3-Phosphate Dehydrogenase

siGFP

silencer RNA against Green Fluorescent Protein

gp130

glycoprotein 130

HLH

Helix-Loop-Helix

ICAM1

Intercellular Adhesion Molecule 1

IκB

inhibitory kappa B

IKK

IκB kinase

IL

interleukin

IM

intramuscular

iNOS

inducible nitric oxide synthase

ITS

Insulin-Transferrin-Sodium selenite

JNK

c-JunN-terminal kinase

KO

knockout

LV

left ventricle/Left Ventricular

LVPWs

Left ventricular posterior wall end systole
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LVPWd

Left ventricular posterior wall end diastole

LVIDs

Left ventricular internal diameter end diastole

LVIDd

Left ventricular internal diameter end diastole

LVVols

left ventricular end systole volume

MAPK

Mitogen-Activated Protein Kinase

MCP-1

Monocyte Chemoattractant Protein 1

MKK

Mitogen-activated Protein Kinase Kinase

MMP

Matrix Metalloproteinase

moi

multiplicity of infection

MT1-MMP

Membrane type I metalloprotease

MTT

(3-(4,5-dimethylthiazolyl-2)-25-diphenyltetrazolium bromide)

NADPH

nicotinamide adenine dinucleotide phosphate reduced

NEMO

NF-κB Essential Modulator

NF-κB

nuclear factor κB

NOX

NADPH oxidase

siNOX4

silencer RNA against NOX4

OD

optical density

qPCR

quantitative PCR

RA

Rheumatoid Arthritis

ROS

Reactive Oxygen Species

SAPK

Stress-Activated Protein Kinase

SBP

Systolic Blood Pressure

SEFIR

Similar Expression to Fibroblast Growth Factor and Interleukin-17
Receptors

shRNA

short hairpin RNA

STIR

SEFIR+TIR

TAK1

Transforming Growth Factor-Beta-Activated Kinase 1

TIMP-1

Tissue Inhibitor of Metalloproteinase 1

TIR

Toll-IL-1 Receptor
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TNFRSF12A

Tumor Necrosis Factor Receptor Superfamily Member 12A

TNFSF12

TNF Superfamily Member 12

TRAF3IP2

TRAF3 Interacting Protein 2

TRAF

TNFR-Associated Factor

TUNEL

Terminal transferase-mediated dUTP-biotin nick end-labeling

TWEAK

TNF-Related Weak Inducer Of Apoptosis

TWEAKR

TWEAK receptor

VCAM1

Vascular Cell Adhesion Molecule 1

WGA

Wheat Germ Agglutinin

WT

wild type
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TWEAK induces ROS-dependent TRAF3IP2 expression in isolated adult mouse cardiac
fibroblasts (CF). TWEAK induced TRAF3IP2 protein expression in CF in a dose-dependent
manner (0.1 to 1000 ng/ml for 1 h; A), with cell death (treatment for 12 h) detected only at
higher doses (B). In cell death analysis (B), H2O2 (100 μM) served as a positive control.
Further, TWEAK (10 ng/ml) induced TRAF3IP2 expression in a time-dependent manner
(C), with peak levels detected at ~1 h. Immunofluorescence revealed low levels of
TRAF3IP2 expression in saline-treated CF and its increased expression following TWEAK
treatment (10 ng/ml for 2 h), localized in cytoplasm (arrow), perinuclear (arrowhead) and
nuclear (block arrow) regions (D). Immunoblotting using cytoplasmic and nuclear extracts
confirmed its nuclear localization (E). Silencing TWEAKR with lentiviral shRNA (moi0.5
for 48 h) or pre-incubation with TWEAKR neutralizing antibodies (ITEM-4, 10 μg/ml for 1
h) inhibited TWEAK (10 ng/ml for 1 h)-induced TRAF3IP2 expression (F). Knockdown of
TWEAKR was confirmed by immunoblotting and is shown on the right (G). gp130 served
as an off-target. Lentiviral shRNA directed against eGFP as well as normal mouse IgG2b
J Mol Cell Cardiol. Author manuscript; available in PMC 2019 September 09.

Das et al.

Page 24

VA Author Manuscript

served as controls. Moreover, TWEAK (10 ng/ml for 30 min) induced oxidative stress as
evidenced by increased generation of hydrogen peroxide (H2O2), an effect attenuated by
TWEAKR (lentiviral TWEAKR shRNA, moi 0.5 for 48 h) or NOX4 (Ad.siNOX4, moi100
for 24 h) knockdown (H). Further, TWEAKR and NOX4 knockdown each attenuated
TWEAK (10 ng/ml for 1 h) -induced TRAF3IP2 expression (I). A, C, E, F, H, I: A
representative image from three independent immunoblotting experiments with similar
results is shown on the left or at the top, and the summarized semi-quantification of intensity
of immunoreactive bands by densitometry from all three experiments on the right or at the
bottom. D, Scale bar: 100 μm. min: minutes, h: hours. B and H, n = 6. *P < at least 0.05
versus untreated, †P < at least 0.05 versus TWEAK, §P < 0.05 versus Untreated.
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TWEAK induces TRAF3IP2-dependent p38 MAPK, NF-κB, and AP-1 activation in cardiac
fibroblasts. TWEAK (10 ng/ml) induced time-dependent p38 MAPK activation (Thr180/
Tyr182 phosphorylation) in CF (A), an effect inhibited by TRAF3IP2 knockdown (lentiviral
shRNA, moi0.5 for 48 h, shown on the right) or pretreatment with the p38 MAPK-specific
inhibitor SB239063 (10 μM in DMSO for 1 h; B). Similarly, TWEAK induced NF-κB
activation (Ser536 phosphorylation of p65) in a time-dependent manner, an effect also
inhibited by TRAF3IP2 knockdown or pre-treatment with SB239063 (D). Further, TWEAK
induced time-dependent JNK (Thr183/Tyr185 phosphorylation) and AP-1 activation (Ser63
phosphorylation of c-Jun) in CF (E), an effect blunted by TRAF3IP2 knockdown (F). A-E:
A representative image from three independent immunoblotting experiments with similar
results is shown at the top and summarized semi-quantification of intensity of
immunoreactive bands by densitometry from all three experiments in the respective bottom
panels. *P < 0.05 versus Untreated, †P < 0.05 versus TWEAK, §P < 0.05 versus Untreated.
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Fig. 3.

TWEAK induces its own expression and that of its receptor (TWEAKR) via TRAF3IP2 and
its downstream signaling intermediates NF-κB and AP-1 in cardiac fibroblasts. TWEAK (10
ng/ml) induced TWEAK expression in a time-dependent manner in CF, and lentiviral
TRAF3IP2 knockdown (moi0.5 for 48 h) inhibited this effect (A; time ‘0’ represents no
exogenous addition of TWEAK). Further, TWEAK upregulated TWEAKR expression in a
time-dependent manner, an effect also blunted by TRAF3IP2 knockdown (B).
Immunofluorescence revealed low levels of TWEAKR expression at basal conditions, and
its increased levels after TWEAK treatment (10 ng/ml for 2 h), localized predominantly in
the membrane at cytoplasm, and its reduced levels following TRAF3IP2 knockdown (C;
arrows denote membrane and cytoplasmic localization of TWEAKR). Moreover,
pretreatment with the p38 MAPK-specific inhibitor SB239063 (10 μM in DMSO for 1 h)
and lentiviral-mediated p65 (moi0.5 for 48 h) and c-Jun (moi0.5 for 48 h) knockdown each

J Mol Cell Cardiol. Author manuscript; available in PMC 2019 September 09.

Das et al.

Page 27

VA Author Manuscript

attenuated TWEAK autoregulation (2 h) and its receptor upregulation (2 h; D). Knockdown
of p65 and c-Jun was confirmed by immunoblotting and is shown on the right in panel E.
gp130 served as an off-target. Further, silencing TRAF3IP2, p65 and c-Jun (moi0.5 for 48 h)
attenuated TWEAK-induced TWEAK (F) and TWEAKR (G) promoter-reporter activities
(both TWEAK and TWEAKR reporters contain 3 kb DNA fragments upstream of
transcription start site and 5’-UTR). Importantly, adenoviral transduction of TRAF3IP2, but
not control GFP, increased TRAF3IP2 protein expression in a dose-dependent manner
(moi1–100 for 24 h) (H), and at a moi50, induced TWEAK and its receptor expression (I).
A, B, D, F, H, I: A representative image from three independent immunoblotting
experiments with similar results is shown on the left and summarized semi-quantification of
intensity of immunoreactive bands by densitometry from all three experiments on the right.
F, G, n = 6. C, Magnification: 40×. *P < at least 0.05 versus untreated, †P < 0.05 versus
TWEAK, §P < 0.05 (n = 3–6).
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Fig. 4.

TWEAK induces the expression of multiple inflammatory mediators in cardiac fibroblasts in
part via TRAF3IP2. Silencing TRAF3IP2 by lentiviral shRNA (moi0.5 for 48 h) inhibited
TWEAK (10 ng/ml for 2 h)-induced cytokine, chemokine, growth factor and adhesion
molecule mRNA expression (RT-qPCR, A). Further, silencing TRAF3IP2 reduced TWEAKinduced cytokine and chemokine secretion (ELISA, B) and protein expression of adhesion
molecules (Immunoblotting, C). C, A representative image from three independent
immunoblot experiments with similar results is shown at the top with summarized semiquantification of intensity of immunoreactive bands by densitometry from all three
experiments in the respective bottom panels. A, B, n = 6, C, n = 3. A-C, *P < at least 0.01
versus untreated, †P < 0.05 versus TWEAK, §P < 0.05 versus Untreated.
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Fig. 5.

TWEAK induces collagen, collagenase and gelatinase expression, and cardiac fibroblast
proliferation and migration in part via TRAF3IP2. TWEAK (10 ng/ml) induced the
expression of fibrillar collagens Iα1 and IIIα1 in a time-dependent manner (A), an effect
blunted by TRAF3IP2 knockdown by lentiviral TRAF3IP2 shRNA (moi0.5 for 48 h) (B).
Further, silencing TRAF3IP2 inhibited TWEAK-induced collagen secretion at 24 h (C;
hydroxyproline assay), the collagenase MMP-13, MMP-14 and TIMP-1 mRNA (RT-qPCR)
and protein expression (immunoblotting) at 2 h (D; protein expression is shown in insets at
the top). Moreover, silencing TRAF3IP2 inhibited activation of the gelatinases MMPs 2 and
9 (E, F; immunoblotting using antibodies that detect both pro and active forms), as well as
CF proliferation (CyQUANT® assay, G) and migration (Matrigel™ migration assay, H). A,
B, D, E, A representative image from three independent immunoblot experiments with
similar results is shown at the top and summarized semi-quantification of intensity of
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immunoreactive bands by densitometry from all three experiments in the respective right
hand or bottom panels. C, G, H, n = 6. A-H, *P < at least 0.05 versus untreated, †P < 0.05
versus TWEAK, §P < 0.05 versus Untreated.
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Fig. 6.

TRAF3IP2 gene deletion blunts TWEAK-induced myocardial hypertrophy and contractile
dysfunction. Both wild type (WT) and homozygous TRAF3IP2 knockout mice (TRAF3IP2KO) were continuously infused with recombinant mouse TWEAK (10 μg/kg body weight/
day) for 7 days via subcutaneously implanted osmotic minipumps (A). Saline-infused
animals served as controls. Systolic blood pressure was measured by tail-cuff
plethysmography (B). Neither saline nor TWEAK affected body weights (C). However,
TWEAK infusion resulted in myocardial hypertrophy, as evidenced by increased heart
weight to body weight ratios (D), cardiomyocyte cross-sectional area (WGA staining; E and
quantification, F) and ANP mRNA expression (RT-qPCR; G) in WT mice, but not in
TRAF3IP2-KO mice. Further, echocardiography revealed myocardial dysfunction in
TWEAK-infused WT, but not TRAF3IP2-KO mice (H), as evidenced by significant
increases in LVPWs (left ventricular posterior wall thickness during systole), LVPWd (left
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ventricular posterior wall thickness during diastole), LVIDd (left ventricular internal
diameter during diastole), LVVols (left ventricular volume in systole) and EF (percent
Ejection Fraction), and reduced LVIDs. B, C, D, F–H, *P < 0.05 versus Saline, †P < 0.05
versus TWEAK (n = 5/group). HW: heart weight, BW: body weight, S: saline; Tw:
TWEAK; WT: wild type; TRAF3IP2-KO: homozygous TRAF3IP2 knockout mice.
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Fig. 7.
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TRAF3IP2 gene deletion blunts TWEAK-induced myocardial fibrosis. Both wild type and
TRAF3IP2-KO mice were continuously infused with TWEAK (10 μg/kg body weight/day)
for 7 days via subcutaneously implanted osmotic minipumps (A). Cardiac fibrosis was
analyzed by Masson’s trichrome (B; quantitative measurement of fibrosis is shown on the
right), collagen Iα1 and collagen IIIα1 mRNA expression (RT-qPCR; C), and collagen and
fibronectin protein expression (immunoblotting; D) in WT mice, and TRAF3IP2 gene
ablation blunted these TWEAK-induced pro-fibrotic responses. While the immunoblots in D
show three individual animals selected at random in each group, the corresponding
summarized semi-quantification data in panel E includes all 5 animals/group. C, E, *P <
0.05 versus untreated, †P < 0.05 versus TWEAK (n = 5/group).
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Fig. 8.

TRAF3IP2 gene deletion blunts TWEAK-induced NF-κB, AP-1 and p38 MAPK activation,
TWEAK and its receptor upregulation, and induction of other inflammatory mediators in the
hypertrophied heart. Both wild type and TRAF3IP2-KO mice were continuously infused
with TWEAK (10 μg/kg body weight/day) for 7 days via subcutaneously implanted osmotic
minipumps (A). TWEAK significantly increased oxidative stress, as evidenced by increased
lipid peroxides (B). Further, TWEAK upregulated TRAF3IP2 expression (C), NF-κB (p65),
AP-1 (c-Jun) and p38 MAPK activation (C), and proinflammatory cytokine (TNF-α, IL-18),
chemokine (MCP-1), adhesion molecule (ICAM1) and iNOS expression (C). These
TWEAK-induced pro-oxidant and proinflammatory effects were blunted by TRAF3IP2 gene
deletion (C). While all the immunoblots in C include three individual animals selected at
random in each group, the corresponding summarized semi-quantification data in panel D
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includes all 5 animals/group. B, D, *P < 0.05 versus untreated, †P < 0.05 versus TWEAK (n
= 5/group).
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Schema showing a critical role for TRAF3IP2 in TWEAK-induced adverse cardiac
remodeling, contractile dysfunction, and heart failure development. TWEAK induced its
own expression and that of TWEAKR by inducing TRAF3IP2-dependent p38 MAPK, NFκB and AP-1 activation, pro-inflammatory and pro-fibrotic cytokin, chemokine, adhesion
molecule, and matrix metalloproteinase (MMP) expression, and fibroblast migration and
proliferation, resulting in adverse cardiac remodeling, contractile dysfunction, and possible
development of heart failure. The membrane localized TWEAK (mTWEAK) is processed
by the serine protease furin, resulting in the release of soluble TWEAK (sTWEAK) that
forms a homotrimer and binds the TWEAKR to initiate the downstream inflammatory
signaling. Notably, TRAF3IP2 deletion blunts these deleterious effects of TWEAK.
Arrowheads denote interventions used in delineating the possible signaling pathways
activated by TWEAK. Broken arrows: TWEAK has previously been shown to activate
MMPs.
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